Congestive heart failure in old age: prevalence, mechanisms and 4‐year prognosis in the Helsinki Ageing Study

Abstract

Abstract. Kupari M, Lindroos M, Iivanainen AM, Heikkila$ J, Tilvis R. (Helsinki University Central Hospital, Helsinki, Finland). Congestive heart failure in old age : prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J Int Med 1997 ; 241 : 387-94.Objective. To examine the prevalence, underlying diseases, abnormalities of left ventricular function and prognosis in congestive heart failure (CHF) of old age. Design. A population-based clinical and echocardiographic study with a 4-year mortality followup. Setting. University hospital. 1904, 1909 and 1914 (367 women). Main outcome measures. Presence of CHF by clinical and chest radiograph criteria ; left ventricular size and systolic function by echocardiography ; grade of aortic and mitral valve lesions by Doppler echocardiography ; 4-year total and cardiovascular mortality. Results. Forty-one of 501 participants (8.2 %) had CHF. Ischaemic heart disease (54 %), hypertension (54 %) and moderate-to-severe mitral or aortic valve Subjects. Five hundred and one individuals born in

Insuficiência cardíaca com fração de ejeção preservada e com disfunção sistólica na comunidade

“…This was the first study to identify this fact in Brazil. The mean age of HF patients was at least 10 years lower than the results of studies conducted in communities in other countries, indicating that our population is more exposed to factors associated with the development of HF 2,6,10,11,[28][29][30][31] . Several studies have shown an increased prevalence of HFpEF with aging, especially in populations of elderly women 2,6,10 .…”

Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: Data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial

“…In the nebivolol group, discontinuation took place because of the following reasons: patient request (16), death (11), loss to follow-up (4), adverse event (stroke) (1), hospitalization (2), and worsening HF (2). In the placebo group, discontinuation took place as follows: patient request (17), death (9), loss to follow-up (1), adverse event (myocardial infarction) (1), patient not taking medication correctly (2), and mandatory indication for h-blocker (1). Most patients who died during the titration phase achieved only small doses of nebivolol.…”

“…In Europe, 6% to 10% of people N65 years of age have HF, and the average age of the patient in the community is 76 years. [1][2][3] The syndrome of HF may arise in presence of either a depressed or apparently normal left ventricular ejection fraction (LVEF). 4 In older patients, HF with preserved LVEF is more common than in younger patients.…”

Prognosis of patients with left ventricular diastolic pressure abnormality: A long-term survival study in patients without coronary artery disease

“…The annual mortality rates in more recent large studies of symptomatic diastolic heart failure were reported to range from 7 to 28% and were mostly due to cardiac deaths, with frequent observations of clinical heart failure and sudden death. 8,19,22,23 Redfield et al found an association between mild DD as defined by Doppler techniques and increased allcause mortality despite a low prevalence of a heart failure diagnosis; however, they noted that the presence of even mild DD was closely associated (22%) with CAD in their study. 24 These findings are at variance with the observations reported in our study, in which the mortality rate of patients with DD and normal EF approximated the adjusted mortality of the general population, and few cardiac deaths occurred.…”